Download Files:
(+)-JNJ-A07
$500 – $4,600
Products Details
Product Description
– (+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models[1].
Web ID
– HY-139602
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– COVID-19-anti-virus
Molecular Formula
– C28H26ClF3N2O6
References
– [1]Kaptein SJF, et al. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction [published correction appears in Nature. 2021 Nov;599(7883):E2]. Nature. 2021;598(7881):504-509.
CAS Number
– 2135640-93-4
Molecular Weight
– 578.96
Compound Purity
– 98.0
SMILES
– OC(CCCOC1=CC(OC)=CC(NC(C2=CC=C(C=C2)Cl)C(N3C4=CC(OC(F)(F)F)=CC=C4CC3)=O)=C1)=O.[Rotation (+)]
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Flavivirus;Virus Protease
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
